NVIV 0.23 InVivo Therapeutics Holdings Corp.
| Range: | 0.22-2.4 | Vol Avg: | 3769288 | Last Div: | 0 | Changes: | -0.17 |
| Beta: | 0.66 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Nov 15 2010 | Empoloyees: | 6 | ||
| CUSIP: | 46186M605 | CIK: | 0001292519 | ISIN: | US46186M6057 | Country: | US |
| CEO: | Dr. Richard M. Toselli M.D. | Website: | https://www.invivotherapeutics.com | ||||
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow